Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration
Sign Up to like & getrecommendations! Published in 2019 at "Scandinavian Journal of Rheumatology"
DOI: 10.1080/03009742.2018.1466363
Abstract: Objectives: To investigate whether smoking habits predict response to rituximab (RTX) in rheumatoid arthritis (RA). Method: We included patients from the CERERRA international cohort receiving the first treatment cycle with available smoking status (n =… read more here.
Keywords: response rituximab; good response; response; disease ... See more keywords
The impact of Fc gamma receptor IIa and IIIa gene polymorphisms on the therapeutic response of rituximab in Egyptian adult immune thrombocytopenic purpura
Sign Up to like & getrecommendations! Published in 2018 at "Hematology"
DOI: 10.1080/10245332.2017.1371479
Abstract: ABSTRACT Background In chronic immune thrombocytopenic purpura (ITP), rituximab removes the harmful autoantibodies through antibody-dependent cellular cytotoxicity. The response to rituximab in ITP is variable; the effectiveness of rituximab is influenced by the process of… read more here.
Keywords: response rituximab; rituximab; response; gene polymorphisms ... See more keywords
Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab.
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1093/rheumatology/keac150
Abstract: OBJECTIVES Secondary inefficacy with infusion reactions and anti-drug antibodies (2NDNR) occurs in 14% of SLE patients receiving repeated rituximab courses. We evaluated baseline clinical characteristics, efficacy and safety of obinutuzumab, a next-generation humanised type-2 anti-CD20… read more here.
Keywords: non response; response rituximab; secondary non; sle patients ... See more keywords
Retrospective analysis of response to rituximab in chronic inflammatory demyelinating polyneuropathy refractory to first‐line therapy
Sign Up to like & getrecommendations! Published in 2021 at "Journal of the Peripheral Nervous System"
DOI: 10.1111/jns.12461
Abstract: Few case reports/series describe the efficacy of rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), which is preferred in the presence of anti‐nodal/paranodal antibodies. We aimed at evaluating the clinical response to rituximab in a… read more here.
Keywords: refractory; inflammatory; rituximab; response rituximab ... See more keywords